Targeted Therapy of Cancer: New Prospects for Antibodies and Immunoconjugates

Authors

  • Dr. Robert M. Sharkey PhD,

    1. Sharkey is Member and Director of Clinical Research, Garden State Cancer Center at the Center for Molecular Medicine and Immunology, Belleville, NJ
    Search for more papers by this author
  • Dr. David M. Goldenberg ScD, MD

    1. Goldenberg is President, Garden State Cancer Center at the Center for Molecular Medicine and Immunology, Belleville, NJ
    Search for more papers by this author

  • 1 This work was supported in part by USPHS grant P01-CA103985 from the National Cancer Institute, NIH, and grant 06-1853-FS-N0 from the New Jersey Department of Health and Senior Services.

  • This article is available online at http://CAonline.AmCancerSoc.org

Abstract

ABSTRACT Immunotherapy of cancer has been explored for over a century, but it is only in the last decade that various antibody-based products have been introduced into the management of patients with diverse cancers. At present, this is one of the most active areas of clinical research, with eight therapeutic products already approved in oncology. Antibodies against tumor-associated markers have been a part of medical practice in immunohistology and in vitro immunoassays for several decades, have even been used as radioconjugates in diagnostic imaging, and are now becoming increasingly recognized as important biological agents for the detection and treatment of cancer. Molecular engineering has improved the prospects for such antibody-based therapeutics, resulting in different constructs and humanized/human antibodies that can be administered frequently. Consequently, a renewed interest in the development of antibodies conjugated with radionuclides, drugs, and toxins has emerged. We review how antibodies and immunoconjugates have influenced cancer detection and therapy, and also describe promising new developments and challenges for broader applications.

Ancillary